Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

AUTODIFF: Autoregressive Diffusion Modeling for Structure-based Drug Design

Structure-based Drug Design with Equivariant Diffusion Models

Binding-Adaptive Diffusion Models for Structure-Based Drug Design

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

A Unified Conditional Diffusion Framework for Dual Protein Targets Based Bioactive Molecule Generation

DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

BInD: Bond and Interaction-generating Diffusion Model for Multi-objective Structure-based Drug Design

FlexSBDD: Structure-Based Drug Design with Flexible Protein Modeling

General Binding Affinity Guidance for Diffusion Models in Structure-Based Drug Design

Rectified Flow For Structure Based Drug Design

Structure-based Drug Design Benchmark: Do 3D Methods Really Dominate?

Interaction-based Retrieval-augmented Diffusion Models for Protein-specific 3D Molecule Generation

Manifold-Constrained Nucleus-Level Denoising Diffusion Model for Structure-Based Drug Design

Autoregressive fragment-based diffusion for pocket-aware ligand design

PackDock: a Diffusion Based Side Chain Packing Model for Flexible Protein-Ligand Docking

Reinforced Genetic Algorithm for Structure-based Drug Design

Leveraging Side Information for Ligand Conformation Generation using Diffusion-Based Approaches

DecompOpt: Controllable and Decomposed Diffusion Models for Structure-based Molecular Optimization

Diff-Shape: A Novel Constrained Diffusion Model for Shape based De Novo Drug Design